Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

In September 2025, the U.S. Food and Drug Administration (FDA) approved several new cancer therapies and supportive care ...

In September 2025, Merck received FDA approval for KEYTRUDA QLEX, a subcutaneous version of its flagship cancer therapy, ...

For the last two years, Keytruda has reigned as the world’s top-selling drug—a distinction under threat with key patent ...

The FDA has cleared the new version for across most of the solid tumour indications already granted for Keytruda, which is ...

Despite flat overall Q2 2025 sales, Keytruda's continued strong performance in oncology supports long-term bullish prospects ...

The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab ...

This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...

The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately to severely ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...